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Clinical PerspectiveWhat Is New?Thirty‐day mortality after transcatheter aortic valve replacement in nonagenarians has improved significantly over the past few years.Procedural complications such as in‐hospital stroke, acute kidney injury, and need for blood transfusion remain associated with increased risk of short‐term mortality.What Are the Clinical Implications?In nonagenarians with severe symptomatic aortic stenosis, transcatheter aortic valve replacement is a safe and feasible option.Appropriate preprocedural planning should be focused on reducing periprocedural complications to improve short‐ and long‐term outcomes.

Introduction {#jah34560-sec-0008}
============

Since its approval by the US Food and Drug Administration in 2011, transcatheter aortic valve replacement (TAVR) has been a breakthrough in the treatment of patients with severe symptomatic aortic stenosis (AS), especially in high‐risk and elderly patients.[1](#jah34560-bib-0001){ref-type="ref"}, [2](#jah34560-bib-0002){ref-type="ref"} Because of improvement in health care, the nonagenarian population continues to expand and is expected to reach \>8.5 million nonagenarians in the United States by 2050.[3](#jah34560-bib-0003){ref-type="ref"} Because AS is a disease of aging, it is expected that the number of nonagenarians with severe AS will rise proportionally.[4](#jah34560-bib-0004){ref-type="ref"}

Nonagenarians were underrepresented in the pivotal TAVR trials, where the mean age of the study population was early 80s.[2](#jah34560-bib-0002){ref-type="ref"}, [5](#jah34560-bib-0005){ref-type="ref"} Although a few studies demonstrated the feasibility of TAVR in nonagenarians,[6](#jah34560-bib-0006){ref-type="ref"}, [7](#jah34560-bib-0007){ref-type="ref"} the available data regarding TAVR outcomes in this population are limited. Prior studies were either limited by small sample sizes from single centers[8](#jah34560-bib-0008){ref-type="ref"}, [9](#jah34560-bib-0009){ref-type="ref"} or by reporting outcomes from the earlier years of TAVR experience,[6](#jah34560-bib-0006){ref-type="ref"}, [10](#jah34560-bib-0010){ref-type="ref"} making the extrapolation of these results to the contemporary era of TAVR suboptimal. Although age is an important element of the Society of Thoracic Surgery risk score, which determines mortality risk with surgical aortic valve replacement, its utility in determining 30‐day mortality with TAVR is unclear.[11](#jah34560-bib-0011){ref-type="ref"}, [12](#jah34560-bib-0012){ref-type="ref"}

The goals of this study are (1) to evaluate changes over time in short‐term outcomes of TAVR nonagenarians; (2) to compare trends in 30‐day mortality among nonagenarians and patients aged 65 to 89 and other short‐term outcomes among patients undergoing TAVR in the last year of the study (2016); and (3) to evaluate factors associated with 30‐day mortality among nonagenarians in 2016, including postprocedural complications and facility TAVR volume. Our findings may help nonagenarian patients and their clinicians reach informed decisions regarding TAVR in this relatively high‐risk population.

Methods {#jah34560-sec-0009}
=======

Study Population {#jah34560-sec-0010}
----------------

Data used for the study are covered under a data use agreement with the Centers for Medicare and Medicaid Services (CMS) and are not available for distribution by the authors but may be obtained from CMS with an approved data use agreement. Requests for statistical and analytic SAS programs used to create the analytic data set may be sent to first author Amgad Mentias (<amgad-mentias@uiowa.edu>). The study cohort was derived from 100% Medicare Provider and Analysis Review (MEDPAR) Part A files for the years 2011--2016, obtained from CMS. We utilized MEDPAR Part A files, which include all hospital discharges for Medicare fee‐for‐service beneficiaries to identify individuals aged ≥65 years who underwent TAVR during 2012--2016 using *International Classification of Diseases, Ninth Revision* (*ICD‐9*) procedure codes for the period through September 2015 (35.05 and 35.06) and *ICD‐10* procedure codes for the period after September 2015 (02RF37Z, 02RF38Z, 02RF3JZ, 02RF3KZ, 02RF37H, 02RF38H, 02RF3JH, 02RF3KH, or X2RF332). In patients who got a second TAVR procedure in follow‐up, only the first procedure was included in our study. Dates of beneficiary Medicare fee‐for‐service enrollment and death were obtained from the 100% Beneficiary Summary and enrollment files for the same period. Patients were excluded if they had been enrolled in Medicare fee‐for‐service for \<12 months before TAVR. Patient characteristics and comorbidities were derived from Medicare enrollment data and inpatient claims during the year before and during the TAVR admission. Patient characteristics included patient age, sex, and race (from the discharge record); dual eligibility for Medicaid (from the Beneficiary Summary file); and preexisting clinical conditions defined using *ICD‐9* or *ICD‐10* codes. Comorbid diseases included 30 conditions defined by Elixhauser et al[13](#jah34560-bib-0013){ref-type="ref"} and additional conditions relevant to patient outcomes (Table [S1](#jah34560-sup-0001){ref-type="supplementary-material"}).

Outcomes {#jah34560-sec-0011}
--------

The study cohort was divided into 2 groups based on age: nonagenarians (90--100 years) and non‐nonagenarians (65--89 years). Patients aged \>100 years were excluded (n=68). We explored 3 outcomes with TAVR in the nonagenarian group across the study period (2012--2016). One outcome was trends of postprocedure complications such as in‐hospital stroke, acute kidney injury (AKI), blood transfusion, respiratory complications, vascular complications, and new permanent pacemaker implantation. The *ICD‐9* and *ICD‐10* codes used to define complications are outlined in Table [S2](#jah34560-sup-0001){ref-type="supplementary-material"}. For in‐hospital complications, a "Present on Admission" indicator was used to identify complications that developed during the TAVR hospitalization.[14](#jah34560-bib-0014){ref-type="ref"} New pacemaker was defined using procedure codes on the same TAVR admission with no prior history of pacemaker. Other outcomes explored were trends of short‐term outcomes (in‐hospital and 30‐day mortality and 30‐day heart failure \[HF\] admissions) and trends in risk‐adjusted rate of 30‐day mortality using generalized estimating equations (GEE) modeling.

Subsequently, we conducted separate analyses of TAVRs performed in 2016 to compare short‐term outcomes among nonagenarians and younger patients undergoing TAVR in 2016; to explore predictors of 30‐day mortality in nonagenarians in 2016; and to evaluate subsequent risk of stroke, bleeding, or heart failure admissions among nonagenarians. In addition to patient characteristics described previously, these analyses also used a validated *ICD‐10*--based frailty index score to study prevalence of frailty in TAVR patients.[15](#jah34560-bib-0015){ref-type="ref"} A score ≥5 is indicative of frailty. *ICD‐9* and *ICD‐10* codes used to define the study outcomes are reported in Table [S2](#jah34560-sup-0001){ref-type="supplementary-material"}. These codes have been validated in prior studies and showed consistent validity.[16](#jah34560-bib-0016){ref-type="ref"}, [17](#jah34560-bib-0017){ref-type="ref"} The institutional review board of the University of Iowa approved this study with a waiver for individual informed consent, given the retrospective nature of the study.

Statistical Analysis {#jah34560-sec-0012}
--------------------

To evaluate trends in short‐term outcomes among nonagenarians, continuous outcomes (eg, length of stay) were described as mean and standard deviation or median and interquartile range, as appropriate, and the trend was assessed with linear regression. Categorical outcomes were described as percentages, and trends were assessed using the Cochran--Armitage test for trend. To assess temporal trends in both groups, we performed the Mantel--Haenszel test for categorical variables.

Subsequently, we used GEE to estimate risk‐adjusted trends in 30‐day mortality among nonagenarians while accounting for clustering of patients in hospitals. Models were adjusted for patient demographics and comorbidities to determine the adjusted relative risk (aRR) and risk‐adjusted 30‐day mortality for each subsequent year compared with 2012. We further included other important factors that are known to affect post‐TAVR mortality and that have changed over time, including procedure characteristics (eg, apical access), and postprocedural complications such as blood transfusion, respiratory complications, vascular complications, and in‐hospital stroke. Because we hypothesized that hospital experience with TAVR is related to improvements in outcomes, we also included a facility‐level measure of TAVR volume, calculated by summarizing all TAVR procedures across hospitals for each given year. A center was considered high‐volume if it performed \>100 TAVR cases per year.[18](#jah34560-bib-0018){ref-type="ref"} To determine magnitude of different factors that might explain the improvement in 30‐day mortality in nonagenarians, we performed the GEE model analysis in a stepwise fashion, adjusting first to change in patient characteristics and then to hospital volumes and change in postprocedure complications. The size of our sample and the number of events recorded permitted the utilization of a modified Poisson regression distribution model and the log link function to estimate RR ratios, as described previously.[19](#jah34560-bib-0019){ref-type="ref"}

We then compared several short‐term outcomes and postprocedure complications among nonagenarians and younger patients (aged 65--90 years) undergoing TAVR in the final study year (2016). Continuous outcomes (eg, length of stay) were compared between the 2 groups using ANOVA or the Mann--Whitney test; categorical outcomes were compared using the χ^2^ test or Fisher exact test, as appropriate. In addition, we compared all‐cause mortality among nonagenarians and younger patients through the end of the follow‐up period (December 2016) using multivariable Cox proportional hazards regression to adjust for age, sex, preexisting comorbidities, TAVR access (apical versus nonapical), and hospital volume. A stepwise backward selection process, guided by the lowest Akaike information criterion to determine the best model fit combined with insight from clinical experience and previous literature, was performed.[20](#jah34560-bib-0020){ref-type="ref"} To assess whether the proportional hazards assumption was violated, a Kolmogorov‐type supremum test and graphical inspection of Schoenfeld residuals plotted against time were performed. Hazard ratios with 95% CIs were calculated. Kaplan--Meier curves with 95% CIs were generated to determine the cumulative proportion of patients who died as a function over time and were compared using log‐rank or generalized Wilcoxon statistics. We then compared 1‐year mortality outcome in nonagenarians with expected survival in an age‐ and sex‐matched US cohort through indirect standardization using actuarial life tables published by the US Social Security Administration.[21](#jah34560-bib-0021){ref-type="ref"} In supplementary analyses, we compared the RR of subsequent stroke, bleeding event, or heart failure admission among nonagenarians and younger patients in 2016 using proportional hazards regression, as detailed in Data [S1](#jah34560-sup-0001){ref-type="supplementary-material"}. For these analyses, patients were censored due to death, Medicare disenrollment, or end of the study period (December 31, 2016).

Finally, we determined predictors of 30‐day mortality in nonagenarians in the last year (2016) using a mixed‐effects multivariable logistic regression with hospitals as a random‐effects variable to account for clustering of patients within hospitals. Patient baseline characteristics were included in multivariable models, with additional analysis that also evaluated the impact of procedural complications on mortality (eg, in‐hospital stroke). Adjusted odds ratios (aORs) are reported with 95% CIs derived from sandwich estimates of standard errors. Goodness of fit was determined with the Hosmer and Lemeshow test, and collinearity was assessed using the variance inflation factor with a cutoff of 2.0.

We performed a sensitivity analysis after excluding apical TAVR procedures. A *P* value of 0.05 was chosen for statistical significance. The analysis was done with SAS v9.4 (SAS Institute) and R 3.4.3 (R Foundation for Statistical Computing).

Results {#jah34560-sec-0013}
=======

Overall, 95 763 TAVR procedures were performed from 2012 to 2016 with nonagenarians comprising 14% (n=13 544) of the population. The number of nonagenarians who underwent TAVR increased from 1209 in 2012 to 4546 in 2016, representing 17.8% and 12.7% of the total TAVR procedures performed in 2012 and 2016, respectively. Table [1](#jah34560-tbl-0001){ref-type="table"} shows changes in nonagenarians' characteristics and comorbidities over the study years, and Table [S3](#jah34560-sup-0001){ref-type="supplementary-material"} shows the changes in younger patients (aged 65--89).

###### 

Trends in Nonagenarians' Comorbidities Over the Study Years

  Variable                      2012   2013   2014   2015   2016   *P* Value
  ----------------------------- ------ ------ ------ ------ ------ -----------
  n                             1209   1847   2549   3393   4546   
  White race                    94.3   94.6   94.8   94.6   94.5   0.9
  Black race                    2.5    2.9    2.6    2.7    2.7    
  Male sex                      49.7   47.2   49.0   47.5   49.5   0.3
  Deficiency anemia             51.4   48.2   46.9   46.7   40.8   \<0.001
  Congestive heart failure      84.8   85.2   84.9   83.9   81.8   \<0.001
  Chronic lung disease          35.2   32.2   30.4   29.5   26.6   \<0.001
  Coagulopathy                  31.8   28.8   28.3   25.3   20.8   \<0.001
  Depression                    12.8   11.0   11.7   11.9   10.7   0.2
  Diabetes mellitus             23.0   24.0   23.0   24.3   24.3   0.6
  Hypertension                  93.5   93.0   93.2   93.5   94.4   0.2
  Hypothyroidism                29.0   31.0   29.8   29.4   30.1   0.7
  Liver disease                 1.3    0.5    0.8    1.0    1.4    0.007
  Lymphoma                      1.3    1.6    1.7    1.1    1.3    0.4
  Electrolyte abnormality       52.1   51.7   50.0   46.9   42.5   \<0.001
  Obesity                       4.8    6.8    7.4    7.7    7.7    0.008
  Peripheral vascular disease   43.3   38.9   35.2   34.9   32.1   \<0.001
  Kidney disease                46.0   45.3   45.1   44.7   43.4   0.3
  Underweight                   11.8   11.0   10.5   9.5    8.4    \<0.001
  Atrial fibrillation           37.8   38.3   36.5   34.5   29.3   \<0.001

Data represented in percentage.
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Trend in Outcomes Over the Study Period {#jah34560-sec-0014}
---------------------------------------

### In‐hospital and short‐term outcomes in nonagenarians {#jah34560-sec-0015}

Table [2](#jah34560-tbl-0002){ref-type="table"} shows the change in unadjusted outcomes in nonagenarians compared with younger patients across the 5 years of the study period. We observed a significant reduction in multiple adverse short‐term outcomes in nonagenarians, including unadjusted rates of in‐hospital mortality (7.5% in 2012, 4.7% in 2014, and 2.4% in 2016; *P* ~trend~\<0.0001), in‐hospital stroke (4.1% in 2012 versus 2.2% in 2016; *P* ~trend~=0.005), 30‐day mortality (9.8% in 2012 versus 3.6% in 2016; *P* ~trend~\<0.0001), and HF admissions (4.1% in 2012 versus 3.0% in 2016; *P* ~trend~=0.02). Length of intensive care unit and hospital stay also declined in nonagenarians, as did the percentage of patients discharged within 72 hours after TAVR increased (7.2% versus 56.4%; *P*\<0.001). Similarly, postprocedure AKI and vascular and respiratory complications declined significantly in nonagenarians over the study period. Although 30‐day mortality also decreased among younger patients (from 6.4% to 2.7%; *P*\<0.001), the relative decrease in mortality among younger patients was roughly 10% smaller than the decrease experienced by nonagenarians (Figure [1](#jah34560-fig-0001){ref-type="fig"}A).

###### 

Trends in Nonagenarians' Procedure Characteristics and Outcomes Over the Study Period

  Variable                                   2012       2013       2014       2015       2016       *P* Value
  ------------------------------------------ ---------- ---------- ---------- ---------- ---------- -----------
  n (n=13 544)                               1209       1847       2549       3393       4546       
  Blood transfusion                          32         31.9       22.4       16.1       9.6        \<0.001
  Length of ICU stay, d, mean±SD             3.3±5.2    3.4±5.0    3.2±5.0    2.6±4.3    2.0±3.5    \<0.001
  Length of hospital stay, d, median (IQR)   5 (4--8)   5 (4--8)   5 (3--7)   4 (3--6)   3 (2--5)   \<0.001
  Early discharge ≤72 h                      7.2        11.4       20.4       35.2       56.4       \<0.001
  Next‐day discharge                         0.4        0.3        1.2        3.9        10.4       \<0.001
  AKI                                        19.8       21.7       19.3       16.1       12.3       \<0.001
  Respiratory complications                  2.8        2.4        1.8        1.6        2.1        0.05
  Vascular complications                     15.6       10.7       10.7       8.3        3.7        \<0.001
  Discharge destination                                                                             
  Home                                       22.1       19.6       23.4       31.3       42.5       \<0.001
  Skilled nursing facility                   30.9       35.0       31.1       25.8       20.4       
  Home health care                           29.1       29.9       31.7       31.0       29.0       
  Inpatient rehabilitation                   7.5        6.7        6.5        6.0        4.0        
  New pacemaker implantation                 26.6       25.8       25.0       26.3       25.1       0.6
  In‐hospital mortality                      7.5        5.6        4.7        3.7        2.4        \<0.0001
  In‐hospital stroke                         4.1        2.7        2.9        2.4        2.2        0.0005
  30‐d mortality                             9.8        7.4        7.1        5.5        3.6        \<0.0001
  30‐d stroke                                4.6        3.0        3.2        2.9        2.7        0.001
  30‐d HF readmissions                       4.1        4.9        3.7        4.2        3.0        0.003
  6‐mo mortality                             21.3       17.4       16.6       14.3       9.8        \<0.0001

Data are shown as percentage except as noted. AKI indicates acute kidney injury; HF, heart failure; ICU, intensive care unit; IQR, interquartile range.
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![**A**, Trend in unadjusted 30‐day mortality rates in nonagenarians and patients aged \<90 years after transcatheter aortic valve replacement. *P* ~trend~\<0.0001. **B**, Trend in risk‐adjusted 30‐day mortality rates in nonagenarians and patients aged \<90 years after transcatheter aortic valve replacement. *P* ~trend~\<0.0001.](JAH3-8-e013685-g001){#jah34560-fig-0001}

### Risk‐adjusted rate of 30‐day mortality in nonagenarians {#jah34560-sec-0016}

After using GEE modeling to adjust for nonagenarians' demographics and comorbidities, risk‐adjusted 30‐day mortality in nonagenarians declined by 54% over the study period (9.8% in 2012 versus 4.4% in 2016; aRR: 0.44; 95% CI, 0.35--0.58; *P*\<0.0001) and was lower in 2016 compared with each individual year in the study (2015: aRR: 0.73; 95% CI, 0.60--0.89; *P*=0.002; 2014: aRR: 0.60; 95% CI, 0.49--0.73; *P*\<0.0001; 2013: aRR: 0.59; 95% CI, 0.47--0.74; *P*\<0.0001; Figure [1](#jah34560-fig-0001){ref-type="fig"}B). Among younger patients, risk‐adjusted 30‐day mortality decreased by ≈46% (from 6.4% to 3.5%, *P*\<0.001)---a roughly 15% smaller decrease than experienced by nonagenarians after adjusting for demographics and comorbidities. Table [S4](#jah34560-sup-0001){ref-type="supplementary-material"} shows the full GEE model for change in 30‐day mortality. When changes in postprocedure complications (in‐hospital stroke, blood transfusion, AKI, vascular and respiratory complications) and center volume were accounted for in the model, the RR of 2016 compared with prior years in nonagenarians was attenuated but remained significant (aRR: 0.54; 95% CI, 0.42--0.70; *P*\<0.001 compared with 2012; aRR: 0.80; 95% CI, 0.66--0.96; *P*=0.02 compared with 2015), whereas high‐volume centers showed a trend with lower 30‐day mortality in the full GEE model (aRR: 0.88; 95% CI, 0.73--1.02; *P*=0.08).

Outcomes With TAVR in Nonagenarians Versus Non‐Nonagenarians in 2016 {#jah34560-sec-0017}
--------------------------------------------------------------------

Table [3](#jah34560-tbl-0003){ref-type="table"} shows baseline characteristics and comorbidities in nonagenarians and non‐nonagenarians in 2016. Nonagenarians had higher prevalence of HF, preexisting atrial fibrillation, and chronic kidney disease and lower prevalence of diabetes mellitus, liver disease, and chronic lung disease. Nonagenarians had slightly higher prevalence of frailty compared with younger patients (31.7% versus 30.0%; *P*=0.02) (Table [S5](#jah34560-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Characteristics of Patients in the 2 Groups in 2016

  Variable                                            Patients \<90 y   Nonagenarians   *P* Value
  --------------------------------------------------- ----------------- --------------- -----------
  n                                                   31 166            4546            
  Age, y, mean (SD)                                   79.6 (7.4)        92.1 (2.0)      
  White race                                          91.8              94.5            \<0.0001
  Black race                                          4.2               2.7             
  Male                                                53.8              49.5            \<0.0001
  Alcohol use                                         2.8               0.8             \<0.0001
  Deficiency anemia                                   40.2              40.8            0.43
  Connective tissue disease                           7.0               5.4             \<0.0001
  Blood loss anemia                                   4.8               4.1             0.03
  Congestive heart failure                            78.5              81.8            \<0.0001
  Chronic lung disease                                38.9              26.6            \<0.0001
  Coagulopathy                                        21.0              20.8            0.87
  Depression                                          15.9              10.7            \<0.0001
  Diabetes mellitus                                   43.9              24.3            \<0.0001
  Hypertension                                        94.2              94.4            0.6
  Hypothyroidism                                      24.7              30.1            \<0.0001
  Liver disease                                       4.4               1.4             \<0.0001
  Lymphoma                                            1.8               1.3             0.003
  Fluid and electrolyte abnormality                   42.5              42.5            0.9
  Obesity                                             27.3              7.7             \<0.0001
  Peripheral vascular disease                         35.3              32.1            0.0001
  Psychosis                                           2.4               1.2             \<0.0001
  Pulmonary circulatory disease                       8.7               7.8             0.1
  Kidney disease                                      41.2              43.4            0.08
  Tumor without metastasis                            5.2               5.0             0.3
  Weight loss                                         8.1               8.4             0.55
  Atrial fibrillation                                 26.6              29.3            0.0002
  Prior stroke                                        17.3              15.5            0.002
  Obstructive sleep apnea                             20.6              6.8             \<0.0001
  Prior smoking                                       19.0              12.5            \<0.0001
  Prior revascularization                             33.1              24.4            \<0.0001
  Coronary artery disease                             32.9              29.4            \<0.0001
  Prior bleeding                                      48.7              46.9            0.03
  Prior pacemaker                                     12.9              19.7            \<0.0001
  Prior implanted defibrillator                       4.4               2.2             \<0.0001
  Apical access                                       3.4               2.2             0.001
  High volume TAVR center                             65.6              66.4            0.33
  Frailty score, mean (SD)                            3.9 (6.0)         4.1 (5.8)       0.001
  Low‐risk score for frailty (score \<5)              70.0              68.3            0.02
  Intermediate‐risk score for frailty (score 5--15)   23.6              25.7            0.002
  High‐risk score for frailty (score \>15)            6.4               6.0             0.25
  CHA~2~DS~2~VASc score                                                                 
  ≤3                                                  9.5               6.9             \<0.001
  4                                                   21.1              21.3            
  5                                                   31.6              36.4            
  6                                                   21.1              20.4            
  ≥7                                                  16.7              15.0            

Data are shown as percentage except as noted. TAVR indicates transcatheter aortic valve replacement.
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### In‐hospital and short‐term outcomes {#jah34560-sec-0018}

In 2016, in‐hospital mortality was higher in nonagenarians compared with non‐nonagenarians (2.4% versus 1.7%; OR: 1.41; 95% CI, 1.15--1.74; *P*=0.001). However, in separate analysis of high‐ and low‐volume centers, we found no significant mortality difference among 2358 nonagenarians and 15 641 younger patients treated in high‐volume centers (2.2% versus 1.7%; OR: 1.33; 95% CI, 0.97--1.81; *P*=0.07), whereas the risk of death was 1.50 times higher in nonagenarians compared with younger patients treated in low‐volume centers (2.6% versus 1.8%; OR: 1.50; 95% CI, 1.13--1.2.00; *P*=0.005). Overall, in‐hospital stroke (2.2% versus 1.8%; *P*=0.04), 30‐day mortality (3.6% versus 2.7%; *P*=0.0002), and 30‐day HF readmissions (3.0% versus 2.1%; *P*\<0.0001) were higher in nonagenarians compared with younger patients. Duration of intensive care unit stay, incidence of AKI, vascular complications, respiratory complications, and new permanent pacemaker implantation were similar in both groups. However, nonagenarians had higher incidence of blood transfusion and longer hospital stay and were less likely to be discharged within 72 hours or discharged home compared with non‐nonagenarians (Table [4](#jah34560-tbl-0004){ref-type="table"}).

###### 

Procedure Measures and Outcomes in Nonagenarians and Patients Aged \<90 Years With TAVR in 2016

  Variable                                   Patients \<90 y   Nonagenarians   *P* Value
  ------------------------------------------ ----------------- --------------- -----------
  n                                          31 166            4546            
  Length of ICU stay, d, median (IQR)        1 (0--2)          1 (0--2)        0.2
  Length of hospital stay, d, median (IQR)   3 (2--4)          3 (2--5)        \<0.01
  Early discharge ≤72 h                      62.7              56.4            \<0.001
  Next‐day discharge                         13.2              10.4            \<0.001
  Blood transfusion                          7.9               9.6             \<0.001
  AKI                                        11.9              12.3            0.42
  Respiratory complications                  2.4               2.1             0.26
  Vascular complications                     3.8               3.7             0.9
  Discharge destination                                                        
  Home                                       56.4              42.5            \<0.001
  Skilled nursing facility                   12.1              20.4            
  Home health care                           25.2              29.0            
  Rehabilitation                             3.1               4.0             
  New pacemaker implantation                 24.4              25.1            0.29
  In‐hospital mortality                      1.7               2.4             0.001
  In‐hospital stroke                         1.8               2.2             0.04
  30‐d mortality                             2.7               3.6             0.003
  30‐d HF readmissions                       2.1               3.0             \<0.001
  30‐d stroke                                2.2               2.7             0.06

Data are shown as percentage except as noted. AKI indicates acute kidney injury; HF, heart failure; ICU, intensive care unit; IQR, interquartile range; TAVR, transcatheter aortic valve replacement.

John Wiley & Sons, Ltd

### All‐cause mortality and secondary outcomes {#jah34560-sec-0019}

In time‐to‐event analysis comparing all‐cause mortality among nonagenarians and younger patients while controlling for patient characteristics, apical access, and facility volume, being a nonagenarian was associated with higher risk of mortality (26.1 versus 17.7 deaths per 100 person‐years; adjusted hazard ratio; 1.50; 95% CI, 1.36--1.66; *P*\<0.001; Figure [2](#jah34560-fig-0002){ref-type="fig"}). When we used data from 2015 for indirect standardization to compare 1‐year mortality with an age‐ and sex‐matched US population,[21](#jah34560-bib-0021){ref-type="ref"} nonagenarians who underwent TAVR in 2015 had 1‐year mortality of 20.4% overall and 20% in high‐volume centers, whereas the age‐ and sex‐matched US population without AS would have expected 1‐year mortality of 18.4%. Results of time‐to‐event analysis for secondary outcomes of stroke, bleeding events, and heart failure in 2016 are shown in Figure [S1A through S1C](#jah34560-sup-0001){ref-type="supplementary-material"}.

![Kaplan--Meier curves for all‐cause mortality after transcatheter aortic valve replacement in nonagenarians and patients aged \<90 years in 2016. Log‐rank test *P*\<0.0001.](JAH3-8-e013685-g002){#jah34560-fig-0002}

### Predictors of 30‐day mortality in nonagenarians in 2016 {#jah34560-sec-0020}

In the multivariable mixed‐effect logistic regression accounting for clustering of patients, important predictors of 30‐day mortality in nonagenarians included in‐hospital stroke (aOR: 8.67; 95% CI, 5.03--15.00), AKI (aOR: 4.11; 95% CI, 2.90--5.83), blood transfusion (aOR: 2.66; 95% CI, 1.81--3.90), respiratory complications (aOR: 2.96; 95% CI, 1.52--5.76), heart failure (aOR: 1.86; 95% CI, 1.04--3.34), and coagulopathy (aOR: 1.59; 95% CI, 1.12--2.26; *P*\<0.05 for all), whereas high‐volume center was not associated with 30‐day mortality in nonagenarians (aOR: 0.77; 95% CI, 0.55--1.07; Figure [3](#jah34560-fig-0003){ref-type="fig"}). Neither frailty nor age was associated with 30‐day mortality in nonagenarians in 2016.

![Adjusted odds ratios (ORs) from mixed‐effects multivariable logistic regression for important predictors of 30‐day mortality after transcatheter aortic valve replacement in nonagenarians in 2016.](JAH3-8-e013685-g003){#jah34560-fig-0003}

Sensitivity Analysis {#jah34560-sec-0021}
--------------------

In a sensitivity analysis, when apical TAVR procedures were excluded, the results of the study remained the same. For example, risk‐adjusted 30‐day mortality in nonagenarians declined from 9.2% in 2012 to 4.3% in 2016, *P* ~trend~\<0.001. In GEE mode, the aRR was the lowest in 2016 compared with each previous year (2012: aRR: 0.47; 95% CI, 0.37--0.61; *P*\<0.001; 2015: aRR: 0.74; 95% CI, 0.61--0.90; *P*=0.003). High‐volume TAVR centers were still associated with lower 30‐day mortality compared with lower volume centers (aRR: 0.84; 95% CI, 0.72--0.99; *P*=0.04). In 2016, in‐hospital mortality was higher in nonagenarians compared with younger patients (2.4% versus 1.6%; *P*\<0.01) but was not different when the analysis was limited to high‐volume centers (2.1% versus 1.6%; *P*=0.053).

Discussion {#jah34560-sec-0022}
==========

In this study using Medicare data, we showed several important findings. First, the number of TAVR procedures done in nonagenarians has increased exponentially over the past few years accompanied by a significant decline in the rate of procedural complications in this population. Second, in‐hospital and 30‐day mortality rates have improved significantly in nonagenarians compared with the earlier years. In fact, in high‐volume centers in 2016, there was no significant difference in in‐hospital mortality between nonagenarians and patients aged \<90 years. Third, we showed that among nonagenarians who underwent TAVR in the last available year, age was not associated with 30‐day mortality. Important procedural outcomes such as in‐hospital stroke, AKI, blood transfusion, and respiratory complications were associated with higher 30‐day mortality and thus may represent potential opportunities to improve overall outcomes in this population.

According to the Social Security Administration, 1 of every 4 people aged 65 years in the United States will live past 90 years, and 1 of every 10 will live past 95 years.[22](#jah34560-bib-0022){ref-type="ref"} As nonagenarians become an expanding cohort in our daily practice, the prevalence of AS in this population will continue to rise. The relatively high frailty in these patients significantly affects the decision of both patients and physicians regarding optimal treatment strategies. Consequently, our study represents an important addition to the literature regarding the most recently available outcomes with TAVR in this high‐risk population.

In our study, we noted a significant decline in vascular complications in nonagenarians from 2012 to 2016. This change is probably related to improvement in the valve profile and smaller delivery systems used in recent years[23](#jah34560-bib-0023){ref-type="ref"} and can explain the decline in blood transfusion rates in nonagenarians in the current study---this complication has always been linked to worse outcomes after TAVR.[24](#jah34560-bib-0024){ref-type="ref"} We also noticed a significant decline in respiratory complications including mechanical ventilation, which is probably a reflection of the increase in the use of conscious sedation versus general anesthesia with TAVR.[25](#jah34560-bib-0025){ref-type="ref"} The improvement in these perioperative complications translated into shorter durations of ICU and hospital stay and an increase in the percentage of patients with early discharge (\<72 hours) after TAVR and with direct discharge home rather than to a skilled care or rehabilitation facility in 2016. Recent studies have shown that earlier discharge for TAVR patients is associated with less morbidity and mortality.[26](#jah34560-bib-0026){ref-type="ref"}, [27](#jah34560-bib-0027){ref-type="ref"} In our GEE model, when we adjusted for changes in nonagenarians' comorbidities across the years, adjusted 30‐day mortality remained significantly lower in 2016 compared with all prior years. Nevertheless, it is possible that these findings could be partially explained by performing TAVR in less frail nonagenarians in recent years.

Procedural volume plays an integral role in influencing outcomes of complex structural procedures like TAVR. In prior studies, both the operator learning curve and the center volume effect had impacts on outcomes with TAVR.[28](#jah34560-bib-0028){ref-type="ref"}, [29](#jah34560-bib-0029){ref-type="ref"}, [30](#jah34560-bib-0030){ref-type="ref"} A recent study showed that center volume remained a significant predictor of mortality even after excluding the TAVR "startup period" for the first 12‐month period in a center.[30](#jah34560-bib-0030){ref-type="ref"} This high‐volume effect might extend to nonagenarians. High‐volume centers in our model were associated with nonsignificant 14% risk reduction in 30‐day mortality after adjusting for all procedural complications in our final GEE model. These procedural complications are indirect mediators through which high‐volume centers might have reduced mortality further, and true risk reduction could be even greater. It is important to note that when we limited the comparison to high‐volume centers only in 2016, there was no significant difference in in‐hospital mortality between nonagenarians and younger patients.

When we used data from 2015, nonagenarians had 1‐year mortality of 20.4% overall and 20% in high‐volume centers. With an indirect standardization method using actuarial life tables published by the Social Security Administration for 2015,[21](#jah34560-bib-0021){ref-type="ref"} an age‐ and sex‐matched US population without AS would have expected 1‐year mortality of 18.4%. Although untreated severe AS at any age is associated with a significant increase in mortality, our study showed that TAVR in nonagenarians with severe AS was associated with a reduction in 1‐year mortality to a percentage that is comparable with an age‐ and sex‐matched US population without AS. This intervention is probably one of the most promising to be performed in such an age group to reduce mortality.

It is worth mentioning that with mixed‐effects logistic regression, none of the patient characteristics or comorbidities other than HF and coagulopathy were associated with 30‐day mortality. Instead, 30‐day mortality was primarily influenced by procedural complications. Periprocedural stroke and AKI were the 2 most important factors that affected short‐term mortality in nonagenarians. In a recent analysis from the PARTNER (Placement of Aortic Transcatheter Valve Trial) study, investigators found that periprocedural stroke and AKI were associated with adjusted hazard ratios of 5.4 and 4.9, respectively, for 1‐year mortality.[31](#jah34560-bib-0031){ref-type="ref"} The mean age in that analysis was 82 years. Stroke and AKI seem to be even more strongly associated with in‐hospital mortality in nonagenarians. Careful monitoring of these potential complications would represent a paramount opportunity to further improve short‐term outcomes, and future innovations should focus on reducing the risk of stroke in the periprocedural period.

Limitations {#jah34560-sec-0023}
-----------

The current study represents the largest and most comprehensive analysis examining outcomes with TAVR in nonagenarian and younger populations and reporting the temporal trend of outcomes over the year using the Medicare database. However, our study has some limitations. First, the most recent CMS data available were from 2016. It will be of great interest to examine the data from more recent years, when available, for more accurate reflection of the contemporary era. Second, frailty and nutritional status are important measures in elderly patients who undergo TAVR, and they affect mortality and outcomes.[32](#jah34560-bib-0032){ref-type="ref"}, [33](#jah34560-bib-0033){ref-type="ref"} We used a recently validated score for frailty using *ICD‐10* codes in 2016 TAVR patients.[15](#jah34560-bib-0015){ref-type="ref"} However, we did not utilize frailty indexes validated using *ICD‐9* codes because it would not be accurate to compare 2 different indexes based on *ICD‐9* and *ICD‐10* codes in different years of the study. Third, despite robust statistical adjustments for comorbidities, there is the possibility of residual confounding from other unmeasured factors. Last, most of the secondary outcomes were derived from *ICD‐9* and *ICD‐10* codes, which are vulnerable to miscoding and misclassification.

Conclusions {#jah34560-sec-0024}
===========

TAVR is increasingly being performed in nonagenarians and elderly patients in the United States, and short‐term outcomes have improved significantly. High‐volume TAVR centers were associated with significant reductions in 30‐day mortality over the years and in periprocedural complications. In‐hospital stroke and AKI remain associated with significant 30‐day hospital mortality in this population.
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